Heart Failure - The Failing Pump
-
Heart failure (HF): a clinical syndrome in which the heart cannot provide adequate output for metabolic needs, or can do so only at elevated filling pressures.
- HFrEF (HF with reduced ejection fraction): LVEF ≤40%
- HFmrEF (HF with mildly reduced ejection fraction): LVEF 41-49%
- HFpEF (HF with preserved ejection fraction): LVEF ≥50%
-
Clinical classifications:
System Stages summary NYHA functional class I: no limitation; II: slight limitation; III: marked limitation; IV: symptoms at rest ACC/AHA stages A: at risk; B: pre-HF; C: symptomatic HF; D: advanced HF
⭐ The most common cause of right-sided heart failure is left-sided heart failure.
Heart Failure - Why It Breaks
Major etiologies
- Ischemic heart disease / prior myocardial infarction: the most common cause of HFrEF; loss of viable myocardium and adverse ventricular remodeling impair systolic function.
- Hypertension: chronic pressure overload causes left ventricular hypertrophy and diastolic dysfunction; it may progress to systolic dysfunction.
- Valvular heart disease: aortic stenosis and chronic hypertension produce pressure overload, whereas mitral or aortic regurgitation produces volume overload.
- Cardiomyopathies and myocarditis: dilated, hypertrophic, restrictive, infiltrative (e.g., amyloidosis), inflammatory, genetic, peripartum, alcohol-related, and cardiotoxic drug-related disease.
- Arrhythmias: persistent tachyarrhythmias can cause tachycardia-induced cardiomyopathy; severe bradyarrhythmias may also precipitate HF.
- Other causes: congenital heart disease, endocrine or metabolic disease (e.g., thyroid disease), pericardial disease, and right-sided pressure overload from pulmonary hypertension or chronic lung disease.
High-output heart failure
Cardiac output may be elevated but still inadequate for excessive tissue demand. Important causes include severe anemia, thyrotoxicosis, large arteriovenous fistula, beriberi, and Paget disease.
Core pathophysiology
- Myocardial injury or abnormal pressure/volume loading reduces effective cardiac performance.
- Reduced renal perfusion activates the sympathetic nervous system and renin-angiotensin-aldosterone system, causing vasoconstriction and sodium-water retention.
- Increased preload and afterload initially support perfusion but later worsen congestion and myocardial workload.
- Chronic neurohormonal activation promotes ventricular hypertrophy, dilation, fibrosis, and adverse remodeling, creating a self-perpetuating cycle of HF.
⭐ Distinguish the underlying cause of HF from a precipitating factor for decompensation. Common precipitants include acute coronary syndrome, uncontrolled hypertension, arrhythmia, infection, medication or dietary nonadherence, renal dysfunction, and pulmonary embolism.
Heart Failure - Spotting Trouble
-
Symptoms: Dyspnea (DOE, orthopnea, PND), fatigue, edema, cough (frothy).
-
Signs: Tachycardia, S3/S4, ↑JVP, edema, creps, hepatomegaly.
-
📌 Mnemonics:
- Left HF (DOABLE): Dyspnea, Orthopnea, Awakening, Basal creps, Lung sounds-wheeze, Expectoration-frothy.
- Right HF (CHAPS): Cor pulmonale, Hepatomegaly, Ascites, Peripheral edema, Splenomegaly.
-
Diagnostic Tools:
- ECG: LVH, prior MI, arrhythmias.
- CXR: Cardiomegaly, pulm. congestion (Kerley B), effusion.
- Echo (key): EF, wall motion, diastolic fx, valves.
- Biomarkers: BNP > 100, NT-proBNP > 300 pg/mL (↑ if renal issues/elderly).
-
Framingham criteria aid CHF diagnosis.
Loading diagram…
⭐ S3 gallop: highly specific for HF, especially with dyspnea.
Heart Failure - Mending Hearts
- Nonpharmacologic care: regular activity or cardiac rehabilitation when stable, vaccination, daily weight monitoring, smoking cessation, and avoidance of excess sodium. Consider fluid restriction (usually 1.5-2 L/day) mainly for severe congestion or hyponatremia rather than routinely for every patient.
- Four foundational therapies for HFrEF-initiate early and titrate as tolerated:
- ARNI (sacubitril/valsartan preferred when appropriate), or an ACE inhibitor/ARB if ARNI cannot be used
- An evidence-based beta-blocker: carvedilol, metoprolol succinate, or bisoprolol
- MRA: spironolactone or eplerenone; monitor potassium and renal function
- SGLT2 inhibitor: dapagliflozin or empagliflozin, irrespective of diabetes status
- Loop diuretics relieve congestion but do not replace mortality-reducing foundational therapy.
- HFpEF: use an SGLT2 inhibitor when appropriate, treat congestion with diuretics, and manage hypertension, atrial fibrillation, obesity, diabetes, chronic kidney disease, ischemia, and sleep apnea.
- Devices after optimized therapy:
- ICD for eligible patients at risk of sudden cardiac death, considering LVEF, symptoms, etiology, expected survival, and timing after myocardial infarction or revascularization.
- CRT has strongest support in symptomatic patients in sinus rhythm with LVEF ≤35%, left bundle branch block, and QRS ≥150 ms despite optimized therapy; selected patients with other QRS patterns or durations may also qualify.
⭐ In eligible patients with chronic symptomatic HFrEF, sacubitril/valsartan reduces cardiovascular death and HF hospitalization compared with enalapril.
Loading diagram…
Heart Failure - Code Blue Crisis
- Definition: acute onset or worsening of HF signs and symptoms requiring urgent evaluation and treatment.
- Common precipitants: acute coronary syndrome, arrhythmia (e.g., atrial fibrillation), infection, uncontrolled hypertension, pulmonary embolism, renal dysfunction, and medication or dietary nonadherence.
- Immediate assessment: airway and work of breathing, oxygen saturation, blood pressure, perfusion, congestion, ECG, renal function/electrolytes, troponin, and the precipitating cause.
- Stevenson profiles and general treatment approach:
- Warm and wet: IV loop diuretic; add a vasodilator when blood pressure is adequate, especially in hypertensive pulmonary edema.
- Cold and wet: IV loop diuretic with close hemodynamic assessment; use an inotrope only for persistent hypoperfusion despite adequate filling, and a vasopressor for cardiogenic shock.
- Cold and dry: if true hypovolemia is suspected, give a cautious fluid challenge; consider an inotrope only if hypoperfusion persists.
- Warm and dry: optimize chronic guideline-directed therapy and address the precipitating factor.
- Give supplemental oxygen only for hypoxemia; use noninvasive ventilation for significant respiratory distress when appropriate.
- In acute pulmonary edema, prioritize an upright position, ventilatory support as needed, nitrates when blood pressure permits, and IV loop diuretics when congestion is present. Routine morphine is not recommended because it may cause respiratory depression and hypotension.
⭐ The cold and wet profile has the worst prognosis because both congestion and hypoperfusion are present; escalation should be guided by blood pressure, perfusion, and shock status.
High‑Yield Points - ⚡ Biggest Takeaways
- Ischemic heart disease is the most common cause of HFrEF.
- NYHA functional class grades symptom-related limitation; ACC/AHA stages describe disease progression.
- BNP/NT-proBNP support diagnosis and prognosis, but values must be interpreted in clinical context.
- The four foundational therapies for HFrEF are an ARNI (or ACE inhibitor/ARB when ARNI is unsuitable), evidence-based beta-blocker, MRA, and SGLT2 inhibitor.
- Sacubitril/valsartan reduces cardiovascular death and HF hospitalization compared with enalapril in eligible patients with chronic symptomatic HFrEF.
- HFpEF management includes an SGLT2 inhibitor when appropriate, diuretics for congestion, and treatment of comorbidities such as hypertension, atrial fibrillation, obesity, diabetes, and chronic kidney disease.
- In acute decompensated HF, assess congestion, perfusion, blood pressure, oxygenation, and the precipitating cause; routine morphine is not recommended.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more